What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH

Survodutide (development code: BI 456906) is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is a once-weekly subcutaneous injection that activates two hormone receptors simultaneously: GLP-1 (for appetite suppression) and glucagon (for increased energy expenditure and direct effects on liver fat).

In a Phase 2 obesity trial of 387 participants, survodutide produced up to 18.7% body weight loss at 46 weeks at the highest dose tested (4.8 mg), with up to 40% of participants achieving 20% or more weight loss. In a separate Phase 2 trial for metabolic dysfunction-associated steatohepatitis (MASH), 83% of participants showed biopsy-proven improvement in liver disease at 48 weeks.

Survodutide is not FDA approved and is not commercially available. Phase 3 trials are ongoing for both obesity and MASH indications.

How Survodutide Works

Dual GLP-1/Glucagon Mechanism

Unlike most next-generation obesity drugs that pair GLP-1 with GIP (as tirzepatide does), survodutide pairs GLP-1 with glucagon. This is a fundamentally different approach. The two receptor components work through complementary mechanisms:

GLP-1 receptor agonism provides the effects familiar from drugs like semaglutide and tirzepatide:

• Reduces appetite by acting on GLP-1 receptors in the hypothalamus
• Slows gastric emptying, prolonging the feeling of fullness after meals
• Stimulates insulin secretion in a glucose-dependent manner
• Suppresses post-meal glucagon from the pancreas

Glucagon receptor agonism adds a distinct metabolic layer that other incretin drugs do not provide:

• Increases energy expenditure — glucagon stimulates thermogenesis and raises resting metabolic rate, meaning the body burns more calories even at rest
• Promotes hepatic fat oxidation — glucagon acts directly on liver cells to increase fat burning, which is why survodutide has particular relevance for MASH
• Stimulates hepatic glycogenolysis — glucagon triggers the liver to break down glycogen stores

Why Glucagon Instead of GIP?

The addition of glucagon is counterintuitive at first glance. Glucagon raises blood sugar — the opposite of what GLP-1 does. In diabetic patients, excess glucagon is considered part of the problem.

The rationale is that the GLP-1 component counterbalances the glucose-raising effect of glucagon, while the glucagon component adds metabolic benefits that GLP-1 alone cannot provide: increased energy expenditure and direct hepatic fat clearance. The result is a drug that attacks obesity from both sides — reducing caloric intake (GLP-1) and increasing caloric output (glucagon).

This is also what differentiates survodutide from retatrutide, which is a triple agonist targeting GLP-1, GIP, and glucagon. Survodutide omits GIP entirely, relying on the GLP-1/glucagon combination alone.

Clinical Trial Data

Phase 2 — Obesity (NCT04667377)

The Phase 2 obesity trial enrolled 387 adults with obesity (BMI 30+) or overweight (BMI 27+ with comorbidities) without diabetes. Participants received once-weekly subcutaneous survodutide or placebo for 46 weeks. Results were dose-dependent, with the weight loss curve still trending downward at study end — meaning the plateau had not yet been reached.

Key findings from the highest dose (4.8 mg):

• 18.7% average body weight loss at 46 weeks — comparable to semaglutide 2.4 mg at 68 weeks (15.3% in STEP 1) but achieved in less time
• Up to 40% of participants lost 20% or more of their body weight
• Weight loss plateau not yet reached at the 46-week mark, suggesting longer treatment could yield even greater reductions
• Dose-dependent response across all four doses tested (0.6 mg, 2.4 mg, 3.6 mg, 4.8 mg)

Phase 2 — MASH (Liver Disease)

The MASH Phase 2 trial studied survodutide in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis. Results at 48 weeks:

The 83% MASH resolution rate is notable. For context, the liver-directed effects are attributed primarily to the glucagon component, which drives hepatic fat oxidation — a mechanism that pure GLP-1 agonists lack. This makes survodutide one of the most promising candidates in the MASH space, alongside retatrutide, which also includes glucagon receptor agonism as part of its triple mechanism.

Survodutide Side Effects

The side effect profile is consistent with the GLP-1 drug class. The most common adverse events reported in Phase 2 trials were gastrointestinal:

• Nausea — the most frequently reported side effect, consistent with all GLP-1 receptor agonists
• Vomiting — more common at higher doses and during the dose escalation period
• Diarrhea — typical of the GLP-1 class

These GI side effects were generally mild to moderate in severity and were most pronounced during the dose titration period. As with other GLP-1 drugs, side effects tended to diminish as patients adjusted to each dose level.

No unexpected safety signals were identified beyond those expected for the GLP-1 drug class. Detailed safety data from the ongoing Phase 3 program will provide a more complete picture.

How Survodutide Compares to Other Drugs

Survodutide occupies a distinct position in the obesity drug landscape. Its 18.7% weight loss from Phase 2 data is strong — exceeding semaglutide — but the comparison is indirect since Phase 2 and Phase 3 results often differ. The Phase 3 program will provide the definitive numbers.

Where survodutide may differentiate most clearly is in MASH. The glucagon component gives it a direct liver-targeting mechanism that pure GLP-1 drugs lack. If the Phase 3 MASH data confirm the Phase 2 results, survodutide could become a leading treatment for both obesity and liver disease simultaneously.

Survodutide vs Retatrutide

Both survodutide and retatrutide include glucagon receptor agonism — a feature that sets them apart from semaglutide and tirzepatide. But they differ in a critical way:

• Survodutide is a dual agonist (GLP-1 + glucagon). It omits GIP entirely and relies on the glucagon component for additional metabolic effects beyond appetite suppression.
• Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). It includes all three receptor targets, producing the highest weight loss numbers seen in clinical trials to date — 28.7% in TRIUMPH-4.

The shared glucagon component means both drugs show strong liver fat reduction and potential MASH benefits. The additional GIP agonism in retatrutide likely contributes to its greater overall weight loss.

For a detailed head-to-head comparison, see our retatrutide vs survodutide article.

Current Status and Availability

• Developer: Boehringer Ingelheim (in partnership with Zealand Pharma)
• Regulatory status: Not FDA approved. Not approved in any country.
• Phase 3 trials: Ongoing for both obesity and MASH indications
• Commercial availability: Not available commercially. Cannot be prescribed or purchased.
• Brand name: None assigned yet

Survodutide is currently only available to participants enrolled in clinical trials. There is no legitimate way to obtain survodutide outside of a clinical trial setting. Any online sources claiming to sell survodutide are unregulated and potentially dangerous.

Frequently Asked Questions

Sources

1. Boehringer Ingelheim. "Survodutide Phase 2 obesity trial results." ClinicalTrials.gov (NCT04667377)
2. Boehringer Ingelheim. "Survodutide Phase 2 MASH trial results." Boehringer Ingelheim Press Release
3. Jastreboff AM, et al. "Retatrutide once weekly for treatment of obesity." New England Journal of Medicine. 2023. NEJM
4. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." New England Journal of Medicine. 2021. NEJM
5. Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)." New England Journal of Medicine. 2022. NEJM

This article is for informational purposes only and does not constitute medical advice. Survodutide is an investigational compound that has not been approved by the FDA or any regulatory authority. Always consult a healthcare provider before starting any medication.